<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364750</url>
  </required_header>
  <id_info>
    <org_study_id>BFIBS</org_study_id>
    <nct_id>NCT04364750</nct_id>
  </id_info>
  <brief_title>Biomarkers of Diet-microbiota Interactions in Irritable Bowel Syndrome</brief_title>
  <official_title>Biomarkers of Diet-microbiota Interactions in Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most patients suffering from the irritable bowel syndrome (IBS) report that ingestion of
      certain foods is a major trigger of symptoms, but the reason is unclear. It has been shown
      that foods containing poorly absorbed carbohydrates are fermented by the bacteria in our
      bowels and these cause symptoms in some but not all patients. These bacteria are also capable
      of producing various products that may be related to IBS symptoms. Our objective is to
      identify specific bacteria or their products that will inform doctors as to whether reducing
      these carbohydrates in the diet will help an individual patient. The study will involve
      approximately 6 weeks on a low-FODMAP diet with three three-day interventions consisting of
      High- or Low-FODMAP drinks along with probiotics or placebo capsules. The patient's bacteria
      and metabolites will be analyzed at various time points.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolites in stool, urine and blood</measure>
    <time_frame>six weeks</time_frame>
    <description>Metabolites will be measured by LC-MS and ELISA at baseline and before and after each intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression of hdc gene by stool bacteria</measure>
    <time_frame>six weeks</time_frame>
    <description>Gram-positive and Gram-negative bacteria will be assessed by PCR using our custom designed primers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool microbiota composition</measure>
    <time_frame>six weeks</time_frame>
    <description>16S rRNA Illumina sequencing of stool samples with culture-enriched sequencing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening of IBS symptoms following High-FODMAP challenges</measure>
    <time_frame>six weeks</time_frame>
    <description>Increase by â‰¥50 points on IBS Symptom Severity Score (IBS-SSS). The score will be used as a dichotomous variable. The overall score ranges from 0 to 500, with higher scores indicating greater symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in IBS symptoms</measure>
    <time_frame>six weeks</time_frame>
    <description>IBS-SSS continuous data. The overall score ranges from 0 to 500, with higher scores indicating greater symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in general GI symptoms</measure>
    <time_frame>six weeks</time_frame>
    <description>Patient-Reported Outcomes Measurement Information System (PROMIS) for general GI symptoms. Four subscales will be used: Gas &amp; Bloating, Diarrhea, Constipation, and Belly Pain. T-scores are calculated using the Scoring Service by Health Measures and range from 34.7 - 79.0 (Gas &amp; Bloating), 39.9 - 75.2 (Diarrhea), 40.6 - 80.8 (Constipation), and 33.9 - 80.0 (Belly Pain). On this scale, 50 indicates the mean of the general population and a difference of 10 is a standard deviation. Higher scores indicate greater symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of anxiety, depression and stress</measure>
    <time_frame>six weeks</time_frame>
    <description>Depression Anxiety Stress Scale (DASS-21) to assess psychiatric comorbidity and stress. The scale scores range from 0 - 42 with higher scores indicating worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in dietary intake</measure>
    <time_frame>six weeks</time_frame>
    <description>5-day food diaries will be completed at 5 time points: baseline, low-FODMAP run-in, and challenges 1,2, and 3. FODMAP intake will be quantified using Monash University software and database</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in group A will undergo challenges in the order:
High-FODMAP beverage + placebo probiotic + L-Histidine
Low-FODMAP beverage + placebo probiotic + L-Histidine
High-FODMAP beverage + probiotic + L-Histidine
Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in group A will undergo challenges in the order:
Low-FODMAP beverage + placebo probiotic + L-Histidine
High-FODMAP beverage + probiotic + L-Histidine
High-FODMAP beverage + placebo probiotic + L-Histidine.
Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in group A will undergo challenges in the order:
High-FODMAP beverage + probiotic + L-Histidine
High-FODMAP beverage + placebo probiotic + L-Histidine
Low-FODMAP beverage + placebo probiotic + L-Histidine.
Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-Histidine</intervention_name>
    <description>1 capsule (0.6g) twice daily</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High-FODMAP beverage</intervention_name>
    <description>High-FODMAP beverage (10g of fermentable carbohydrates) consumed twice daily.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low-FODMAP beverage</intervention_name>
    <description>Low-FODMAP beverage (10g glucose) consumed twice daily.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2.</intervention_name>
    <description>Total of 50 billion CFU/capsule taken twice daily.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <other_name>Bio-K+ 50 Billion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Enteric coated capsule with no active ingredient, taken twice daily</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 18-75 with IBS (Rome IV criteria) who have also self-reported previous
             improvement in their IBS symptoms while on a low FODMAP diet, or when excluding
             certain high-FODMAP foods, or patients in whom histamine is expected to play a key
             role (either diagnosed with high histamine producing bacteria, or improved IBS
             symptoms after using antihistamines). Individuals should be able to swallow size 00
             capsules.

        Exclusion Criteria:

          -  Concurrent significant organic GI pathology (i.e. celiac, IBD, etc.)

          -  Concurrent systemic disease (such as diabetes) and/or laboratory abnormalities
             considered by investigators to be risky or that could interfere with data collection

          -  History of active cancer in the last 5 years, other than basal cell cancer

          -  Pregnant or breastfeeding women

          -  Active or recent participation (&lt; 1 month) in a clinical study, except for SPOR
             IMAGINE

          -  Use of antibiotics, probiotics, antihistamines, or ACE inhibitors during, or one month
             prior to the study

          -  Use of new medications less than 4 weeks prior to the study.

          -  Allergies to any of the ingredients used in the study

          -  Any immune-compromising conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Premysl Bercik, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro Miranda, PhD</last_name>
    <phone>9055212100</phone>
    <phone_ext>21875</phone_ext>
    <email>mirandp@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carolina Duque, BSc</last_name>
    <phone>9055212100</phone>
    <phone_ext>21875</phone_ext>
    <email>duquec@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McMaster University Medical Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Pedro Miranda, PhD</last_name>
      <phone>9055212100</phone>
      <phone_ext>21875</phone_ext>
      <email>mirandp@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Carolina Duque, BSc</last_name>
      <phone>9055212100</phone>
      <phone_ext>21875</phone_ext>
      <email>duquec@mcmaster.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Premysl Bercik, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Celine Morissette</last_name>
      <phone>(613) 544-3400</phone>
      <phone_ext>2479</phone_ext>
      <email>celine.morissette@kingstonhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Stephen Vanner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FODMAP</keyword>
  <keyword>microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

